Jianyi Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jianyi Ding has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Andre Larochelle
Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20892, USA
2 shared publications - Chunzhang Yang
Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA
2 shared publications Junjie Gu
Basic Clinical Research Center, Renji Hospital, Department of Histoembryology, Genetics and Developmental Biology, Shanghai Key Laboratory of Reproductive Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications- Ying Jin
Department of Histoembryology, Genetics and Developmental Biology, Shanghai Key Laboratory of Reproductive Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications Zhexin Zhu
CAS Key Laboratory of Tissue Microenvironment and Tumor, Chinese Academy of Sciences, Shanghai, China
2 shared publicationsChenlin Zhou
Key Laboratory of Stem Cell Biology, CAS Center for Excellence in Molecular Cell Science, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences/Shanghai JiaoTong University School of Medicine, 320 Yueyang Road, Shanghai 200032, China
1 shared publication
Latest Publications
- Open Access
- 30 September 2026
- Published by Springer Nature in Cell Death & Disease
CD38 inhibition preserves adult human hematopoietic stem cells
In humans, long-term hematopoietic stem cells (LT-HSCs) are enriched within the CD34⁺CD38 low fraction in vivo, and CD38 abundance typically rises with lineage commitment, suggesting that CD38 may function as a negative regulator of stem cell function. Here, we show that pharmacologic CD38 inhibition with 78c during 7-day culture preserves adult human LT-HSC repopulating activity, yielding durable primary and secondary engraftment and limiting-dilution-estimated LT-HSC frequencies comparable to uncultured controls. Transcriptomic and proteomic profiling revealed coordinated repression of PI3K–AKT–mTOR–linked anabolic and G₁–S programs, with increased signatures of quiescence, chromatin compaction, and stress resilience. Pharmacologic inhibition of mTOR, PI3K, or CDK activity phenocopied the effects of 78c on cell cycle restraint and HSC maintenance. These findings support a model in which CD38 inhibition restrains mTOR-gated entry into cycle in cytokine-stimulated cultures, and identify CD38 inhibition as a tractable strategy to preserve adult human LT-HSCs ex vivo.
- 30 September 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessCD38 inhibition preserves adult human hematopoietic stem cells
In humans, long-term hematopoietic stem cells (LT-HSCs) are enriched within the CD34⁺CD38 low fraction in vivo, and CD38 abundance typically rises with lineage commitment, suggesting that CD38 may function as a negative regulator of stem cell function. Here, we show that pharmacologic CD38 inhibition with 78c during 7-day culture preserves adult human LT-HSC repopulating activity, yielding durable primary and secondary engraftment and limiting-dilution-estimated LT-HSC frequencies comparable to uncultured controls. Transcriptomic and proteomic profiling revealed coordinated repression of PI3K–AKT–mTOR–linked anabolic and G₁–S programs, with increased signatures of quiescence, chromatin compaction, and stress resilience. Pharmacologic inhibition of mTOR, PI3K, or CDK activity phenocopied the effects of 78c on cell cycle restraint and HSC maintenance. These findings support a model in which CD38 inhibition restrains mTOR-gated entry into cycle in cytokine-stimulated cultures, and identify CD38 inhibition as a tractable strategy to preserve adult human LT-HSCs ex vivo.
- Open Access
De Novo Generation of Human Hematopoietic Stem Cells from Pluripotent Stem Cells for Cellular Therapy
The ability to manufacture human hematopoietic stem cells (HSCs) in the laboratory holds enormous promise for cellular therapy of human blood diseases. Several differentiation protocols have been developed to facilitate the emergence of HSCs from human pluripotent stem cells (PSCs). Most approaches employ a stepwise addition of cytokines and morphogens to recapitulate the natural developmental process. However, these protocols globally lack clinical relevance and uniformly induce PSCs to produce hematopoietic progenitors with embryonic features and limited engraftment and differentiation capabilities. This review examines how key intrinsic cues and extrinsic environmental inputs have been integrated within human PSC differentiation protocols to enhance the emergence of definitive hematopoiesis and how advances in genomics set the stage for imminent breakthroughs in this field.
Open AccessDe Novo Generation of Human Hematopoietic Stem Cells from Pluripotent Stem Cells for Cellular Therapy
The ability to manufacture human hematopoietic stem cells (HSCs) in the laboratory holds enormous promise for cellular therapy of human blood diseases. Several differentiation protocols have been developed to facilitate the emergence of HSCs from human pluripotent stem cells (PSCs). Most approaches employ a stepwise addition of cytokines and morphogens to recapitulate the natural developmental process. However, these protocols globally lack clinical relevance and uniformly induce PSCs to produce hematopoietic progenitors with embryonic features and limited engraftment and differentiation capabilities. This review examines how key intrinsic cues and extrinsic environmental inputs have been integrated within human PSC differentiation protocols to enhance the emergence of definitive hematopoiesis and how advances in genomics set the stage for imminent breakthroughs in this field.
- Top Cited PapersOpen Access
- 15 April 2020
- Published by Springer Nature in British Journal of Cancer
- Vol. 122 (11) , 1580-1589
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety of human malignancies, including gliomas, acute myeloid leukaemia, cholangiocarcinoma, chondrosarcoma and thyroid carcinoma. A series of seminal studies further elucidated the biological impact of the IDH mutation and uncovered the potential role of IDH mutants in oncogenesis. Notably, the neomorphic activity of the IDH mutants establishes distinctive patterns in cancer metabolism, epigenetic shift and therapy resistance. Novel molecular targeting approaches have been developed to improve the efficacy of therapeutics against IDH-mutated cancers. Here we provide an overview of the latest findings in IDH-mutated human malignancies, with a focus on glioma, discussing unique biological signatures and proceedings in translational research.
- 15 April 2020
- Published by Springer Nature in British Journal of Cancer
- Vol. 122 (11) , 1580-1589
Top Cited PapersOpen AccessIDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety of human malignancies, including gliomas, acute myeloid leukaemia, cholangiocarcinoma, chondrosarcoma and thyroid carcinoma. A series of seminal studies further elucidated the biological impact of the IDH mutation and uncovered the potential role of IDH mutants in oncogenesis. Notably, the neomorphic activity of the IDH mutants establishes distinctive patterns in cancer metabolism, epigenetic shift and therapy resistance. Novel molecular targeting approaches have been developed to improve the efficacy of therapeutics against IDH-mutated cancers. Here we provide an overview of the latest findings in IDH-mutated human malignancies, with a focus on glioma, discussing unique biological signatures and proceedings in translational research.
- Open Access
Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma
Succinate dehydrogenase subunit B (SDHB) deficiency frequently occurs in cluster I pheochromocytomas and paragangliomas (PCPGs). SDHB-mutated PCPGs are characterized by alterations in the electron transport chain, metabolic reprogramming of the tricarboxylic cycle, and elevated levels of reactive oxygen species (ROS). We discovered that SDHB-deficient PCPG cells exhibit increased oxidative stress burden, which leads to elevated demands for glutathione metabolism. Mechanistically, nuclear factor erythroid 2-related factor 2 (NRF2)-guided glutathione de novo synthesis plays a key role in supporting cellular survival and the proliferation of SDHB-knockdown (SDHBKD) cells. NRF2 blockade not only disrupted ROS homeostasis in SDHB-deficient cells but also caused severe cytotoxicity by the accumulation of DNA oxidative damage. Brusatol, a potent NRF2 inhibitor, showed a promising effect in suppressing SDHBKD metastatic lesions in vivo, with prolonged overall survival in mice bearing PCPG allografts. Our findings highlight a novel therapeutic strategy of targeting the NRF2-driven glutathione metabolic pathway against SDHB-mutated PCPG.
Open AccessTargeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma
Succinate dehydrogenase subunit B (SDHB) deficiency frequently occurs in cluster I pheochromocytomas and paragangliomas (PCPGs). SDHB-mutated PCPGs are characterized by alterations in the electron transport chain, metabolic reprogramming of the tricarboxylic cycle, and elevated levels of reactive oxygen species (ROS). We discovered that SDHB-deficient PCPG cells exhibit increased oxidative stress burden, which leads to elevated demands for glutathione metabolism. Mechanistically, nuclear factor erythroid 2-related factor 2 (NRF2)-guided glutathione de novo synthesis plays a key role in supporting cellular survival and the proliferation of SDHB-knockdown (SDHBKD) cells. NRF2 blockade not only disrupted ROS homeostasis in SDHB-deficient cells but also caused severe cytotoxicity by the accumulation of DNA oxidative damage. Brusatol, a potent NRF2 inhibitor, showed a promising effect in suppressing SDHBKD metastatic lesions in vivo, with prolonged overall survival in mice bearing PCPG allografts. Our findings highlight a novel therapeutic strategy of targeting the NRF2-driven glutathione metabolic pathway against SDHB-mutated PCPG.
- 15 October 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 235 (5) , 4279-4290
CDK11 safeguards the identity of human embryonic stem cells via fine‐tuning signaling pathways
Signaling pathways transmit extracellular cues into cells and regulate transcriptome and epigenome to maintain or change the cell identity. Protein kinases and phosphatases are critical for signaling transduction and regulation. Here, we report that CDK11, a member of the CDK family, is required for the maintenance of human embryonic stem cell (hESC) self‐renewal. Our results show that, among the three main isoforms of CDK11, CDK11p46 is the main isoform safeguarding the hESC identity. Mechanistically, CDK11 constrains two important mitogen‐activated protein kinase (MAPK) signaling pathways (JNK and p38 signaling) through modulating the activity of protein phosphatase 1. Furthermore, CDK11 knockdown activates transforming growth factor β (TGF‐β)/SMAD2/3 signaling and upregulates certain nonneural differentiation‐associated genes. Taken together, this study uncovers a kinase required for hESC self‐renewal through fine‐tuning MAPK and TGF‐β signaling at appropriate levels. The kinase‐phosphatase axis reported here may shed new light on the molecular mechanism sustaining the identity of hESCs.
- 15 October 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 235 (5) , 4279-4290
CDK11 safeguards the identity of human embryonic stem cells via fine‐tuning signaling pathways
Signaling pathways transmit extracellular cues into cells and regulate transcriptome and epigenome to maintain or change the cell identity. Protein kinases and phosphatases are critical for signaling transduction and regulation. Here, we report that CDK11, a member of the CDK family, is required for the maintenance of human embryonic stem cell (hESC) self‐renewal. Our results show that, among the three main isoforms of CDK11, CDK11p46 is the main isoform safeguarding the hESC identity. Mechanistically, CDK11 constrains two important mitogen‐activated protein kinase (MAPK) signaling pathways (JNK and p38 signaling) through modulating the activity of protein phosphatase 1. Furthermore, CDK11 knockdown activates transforming growth factor β (TGF‐β)/SMAD2/3 signaling and upregulates certain nonneural differentiation‐associated genes. Taken together, this study uncovers a kinase required for hESC self‐renewal through fine‐tuning MAPK and TGF‐β signaling at appropriate levels. The kinase‐phosphatase axis reported here may shed new light on the molecular mechanism sustaining the identity of hESCs.
- 1 February 2017
- Published by Elsevier in Cell Stem Cell
- Vol. 20 (2) , 274-289.e7
PHB Associates with the HIRA Complex to Control an Epigenetic-Metabolic Circuit in Human ESCs
- 1 February 2017
- Published by Elsevier in Cell Stem Cell
- Vol. 20 (2) , 274-289.e7
PHB Associates with the HIRA Complex to Control an Epigenetic-Metabolic Circuit in Human ESCs